A-CHMINACA

Last updated

A-CHMINACA
A-CHMINACA.svg
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible) [a]
Identifiers
  • N-(1-adamantyl)-1-(cyclohexylmethyl)indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C25H33N3O
Molar mass 391.559 g·mol−1
3D model (JSmol)
  • C1CCC(CC1)CN2C3=CC=CC=C3C(=N2)C(=O)NC45CC6CC(C4)CC(C6)C5
  • InChI=1S/C25H33N3O/c29-24(26-25-13-18-10-19(14-25)12-20(11-18)15-25)23-21-8-4-5-9-22(21)28(27-23)16-17-6-2-1-3-7-17/h4-5,8-9,17-20H,1-3,6-7,10-16H2,(H,26,29)
  • Key:ACFKPINHOINOFB-UHFFFAOYSA-N

A-CHMINACA, (ACHMINACA, Adamantyl-CHMINACA, SGT-37), is an indazole-based synthetic cannabinoid that binds to the CB1 and CB2 receptors. [2] [3]

Contents

It has an EC50 of 159 nM for human CB1 receptors. [4]

Metabolism

A-CHMINACA is not hydrolized by human carboxylesterases which increases its half-life. [5]

Distribution

A-CHMINACA has been sold as a designer drug with one sample having been seized by Polish authorities in Lublin. [6]

It was also detected in samples taken in Toronto in 2020. [7]

See also

References

  1. ↑ NpSG blanket ban [1]
  1. ↑ "Anlage NpSG". Einzelnorm (in German). Retrieved 2025-09-10.
  2. ↑ "Substance Details Adamantyl-CHMINACA". United Nations : Office on Drugs and Crime. Retrieved September 10, 2025.
  3. ↑ Miller JJ, Yazdanpanah M, Colantonio DA, Beriault DR, Delaney SR (Dec 2024). "New Psychoactive Substances: A Canadian perspective on emerging trends and challenges for the clinical laboratory". Clinical Biochemistry. 133–134 110810. Elsevier BV. doi:10.1016/j.clinbiochem.2024.110810. ISSN   0009-9120. PMID   39181179.
  4. ↑ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 16, 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA" . ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. ISSN   1948-7193. PMID   33253529 . Retrieved September 10, 2025.
  5. ↑ Wagmann L, Stiller RG, Fischmann S, Westphal F, Meyer MR (July 5, 2022). "Going deeper into the toxicokinetics of synthetic cannabinoids: in vitro contribution of human carboxylesterases" (PDF). Archives of Toxicology. 96 (10). Springer Science and Business Media LLC: 2755–2766. Bibcode:2022ArTox..96.2755W. doi: 10.1007/s00204-022-03332-z . ISSN   0340-5761. PMC   9352624 . PMID   35788413 . Retrieved September 10, 2025.
  6. ↑ Dybowski MP, Holowinski P, Typek R, Dawidowicz AL (2021). "Comprehensive analytical characteristics of N-(adamantan-1-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide (ACHMINACA)" (PDF). Forensic Toxicology. 39 (1): 230–239. doi: 10.1007/s11419-020-00547-6 . ISSN   1860-8965 . Retrieved September 10, 2025.
  7. ↑ Scarfone KM, Maghsoudi N, McDonald K, Thompson H, Stefan C, Beriault DR, et al. (August 3, 2022). "Emerging synthetic cannabinoids detected by a drug checking service in Toronto, Canada" . Clinical Toxicology. 60 (8): 979–984. doi:10.1080/15563650.2022.2069575. ISSN   1556-3650. PMID   35546568 . Retrieved September 10, 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.